Novartis/Amgen Aimovig shows positive effect in episodic migraine

• Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN) present results reinforcing the long-term safety and efficacy profile of Aimovig (erenumab-aooe) in patients with episodic migraine (EM) at the Migraine Trust Virtual Symposium.
• Results from the five-year, open-label treatment period of a Phase 2 study in EM prevention showed Aimovig helped patients achieve sustained reductions in monthly migraine days (MMD) and in use of acute migraine-specific medication (AMSM), such as triptans.
• The study enrolled 383 patients with EM who completed a 12-week double-blind, placebo-controlled treatment period (DBTP). Average MMD reduction was 5.3 days from the DBTP baseline of 8.7 days.
• Patients who used AMSM to treat their migraine headaches experienced an average reduction in AMSM use of 4.4 days from the DBTP baseline of 6.2. The most common side effects were nasopharyngitis, upper respiratory tract infection and influenza.
• The safety profile was consistent with the double-blind treatment phase of the study, with no increases in adverse event rates over five years of exposure.
• Additional studies highlighting Aimovig will be presented at the Migraine Trust Virtual Symposium, including interim results of the LIBERTY open-label extension study as well as efficacy and safety results of Aimovig in the EMPOwER study.
• https://seekingalpha.com/news/3619662-novartis-amgen-aimovig-shows-positive-effect-in-patients-episodic-migraine